We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-6.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$647M
AUM Growth
-$83.7M
Cap. Flow
-$10M
Cap. Flow %
-1.55%
Top 10 Hldgs %
49.16%
Holding
110
New
21
Increased
23
Reduced
14
Closed
30

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$30.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$24M
3
NVO
Novo Nordisk
NVO
+$22.8M
4
PTCT icon
PTC Therapeutics
PTCT
+$13.5M
5
GILD icon
Gilead Sciences
GILD
+$13.4M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$31.8M
2
GSK icon
GSK
GSK
+$20M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$19.3M
4
VRNT
Verint Systems
VRNT
+$15.6M
5
BLUE
bluebird bio
BLUE
+$9.54M

Sector Composition

Rank Sector Weight
1 Healthcare 74.15%
2 Technology 11.83%
3 Industrials 2.25%
4 Consumer Discretionary 1.19%
5 Communication Services 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BURL icon
51
Burlington
BURL
$23.2B
$3.9M 0.6%
19,500
– –
STRO icon
52
Sutro Biopharma
STRO
$401M
$3.84M 0.59%
42,259
-2,330
-5% -$235K
TVTX icon
53
Travere Therapeutics
TVTX
$5.2B
$3.83M 0.59%
330,203
-200,475
-38% -$3.31M
AMZN icon
54
Amazon
AMZN
$2.92T
$3.82M 0.59%
44,000
-40,000
-48% -$3.71M
ITRN icon
55
Ituran Location and Control
ITRN
$1.09B
$3.35M 0.52%
135,311
+5,311
+4% +$151K
ACAD icon
56
Acadia Pharmaceuticals
ACAD
$4.43B
$3.24M 0.5%
+90,000
New +$2.73M
BPMC
57
DELISTED
Blueprint Medicines
BPMC
$3.12M 0.48%
+42,500
New +$3.67M
DTIL icon
58
Precision BioSciences
DTIL
$180M
$3.06M 0.47%
12,167
+1,000
+9% +$325K
AKRO
59
DELISTED
Akero Therapeutics
AKRO
$2.96M 0.46%
+130,000
New +$3.02M
WAB icon
60
Wabtec
WAB
$49.1B
$2.87M 0.44%
40,000
– –
ALNA
61
DELISTED
Allena Pharmaceuticals
ALNA
$2.65M 0.41%
673,881
+182,688
+37% +$784K
FVRR icon
62
Fiverr
FVRR
$321M
$2.64M 0.41%
141,355
+71,355
+102% +$1.63M
CHTR icon
63
Charter Communications
CHTR
$17.3B
$2.47M 0.38%
6,000
– –
ARYAU
64
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
$2.19M 0.34%
200,000
– –
DK icon
65
Delek US
DK
$4.16B
$1.81M 0.28%
50,000
+41,653
+499% +$1.53M
TECX
66
Tectonic Therapeutic
TECX
$529M
$1.78M 0.28%
+10,527
New +$2.38M
NVMI
67
Nova
NVMI
$12.4B
$1.65M 0.25%
+51,949
New +$1.48M
VIRX
68
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.54M 0.24%
+61,194
New +$1.77M
ASMB icon
69
Assembly Biosciences
ASMB
$498M
$1.18M 0.18%
+10,000
New +$1.51M
PRVL
70
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$1.11M 0.17%
90,217
-40,713
-31% -$461K
HSACU
71
DELISTED
Health Sciences Acquisitions Corporation Units
HSACU
$1.07M 0.17%
100,000
– –
CNCE
72
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$823K 0.13%
+140,000
New +$1.49M
BLCM
73
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$788K 0.12%
+75,000
New +$980K
ABUS icon
74
Arbutus Biopharma
ABUS
$857M
$763K 0.12%
500,000
– –
XFOR icon
75
X4 Pharmaceuticals
XFOR
$375M
$602K 0.09%
1,580
– –
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2019 Portfolio in Review

As of Q3 2019, Sphera Funds Management held 110 positions worth $647M, down 11% from $731M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sphera Funds Management's Q3 2019 filing shows 21 new, 23 increased, 14 reduced and 30 closed positions. Its largest new stake was Sanofi: 700,000 shares worth $32.4M. The largest sale was AstraZeneca, an estimated $31.8M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 70% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q3 2019 buy was Sanofi: 700,000 shares worth $32.4M.
  • Sphera Funds Management added most to Sarepta Therapeutics in Q3 2019, an estimated $24M increase.
  • Sphera Funds Management's biggest Q3 2019 reduction was Alexion Pharmaceuticals, cutting an estimated $19.3M.
  • Sphera Funds Management fully exited AstraZeneca in Q3 2019, selling an estimated $31.8M.
  • Sphera Funds Management's ten largest holdings make up 49% of its $647M portfolio in Q3 2019.
  • Sphera Funds Management opened 21 new positions and closed 30 in Q3 2019.
  • Sphera Funds Management's portfolio value fell 11% quarter-over-quarter to $647M.

Based on Sphera Funds Management's 13F filing for Q3 2019, filed 14 Nov 2019.